Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 8/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 14/20 | 0.49 |
| ▸ | LCK | P06239 | 7/20 | 0.49 |
| ▸ | TEK | Q02763 | 7/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.33 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3778703 | 0.86 | BRAF (0.53) | BRAFRAF1KDRLCKTEK | |
| SCHEMBL3643127 | 0.83 | BRAF (0.51) | BRAFRAF1KDRLCKTEK | |
| SCHEMBL3643339 | 0.81 | BRAF (0.52) | BRAFRAF1KDRLCKTEK | |
| SCHEMBL3770500 | 0.81 | BRAF (0.50) | BRAFRAF1KDRLCKTEK | |
| SCHEMBL3647099 | 0.81 | BRAF (0.53) | BRAFRAF1KDRLCKTEK | |
| SCHEMBL3769355 | 0.79 | BRAF (0.49) | BRAFRAF1KDRLCKTEK | |
| SCHEMBL2516044 | 0.77 | BRAF (0.65) | BRAFRAF1KDRLCKTEK | |
| SCHEMBL3637785 | 0.76 | BRAF (0.48) | BRAFRAF1KDRLCKTEK | |
| SCHEMBL3645004 | 0.74 | BRAF (0.55) | BRAFRAF1KDRLCKTEK | |
| SCHEMBL3641578 | 0.74 | KDR (0.53) | BRAFRAF1KDRLCKTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005198-A1 | RAF KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2014-01-02 | — | — | US | claimed |
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-12-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885KDR 700/4885 |
| US-20140005198-A1 | RAF KINASE MODULATORS AND METHODS OF USE | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885KDR 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.